Staphylococcus lugdunensis: Difference between revisions
| Line 5: | Line 5: | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2010</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2010</ref>== | ||
'''Antibiotic''' '''No. (%) susceptible''' | |||
Penicillin G 403 (74.6) | |||
Gentamicin 538 (99.6) | |||
Rifampicin 538 (99.6) | |||
Cefoxitin 538 (99.6) | |||
Fusidic acid 528 (97.8) | |||
Trimethoprim/sulfamethoxazole 539 (99.8) | |||
Norfloxacin 539 (99.8) | |||
Clindamycin 494 (91.5) | |||
Erythromycin 506 (93.7) | |||
===Key=== | ===Key=== | ||
Revision as of 19:22, 21 December 2020
Background
- Staphylococcus lugdunensis is a coagulase-negative staphylococcus with unusual pathogenicity resembling that of S. aureus[1]
- A Gram Positive Bacteria
- Causes endocarditis, meningitis, and Skin and Soft Tissue Infections
Antibiotic Sensitivities[2]
Antibiotic No. (%) susceptible Penicillin G 403 (74.6) Gentamicin 538 (99.6) Rifampicin 538 (99.6) Cefoxitin 538 (99.6) Fusidic acid 528 (97.8) Trimethoprim/sulfamethoxazole 539 (99.8) Norfloxacin 539 (99.8) Clindamycin 494 (91.5) Erythromycin 506 (93.7)
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||
See Also
References
- ↑ Taha L, Stegger M, and Soderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options, European Journal of Clinical Microbiology & Infectious Diseases, May 2019. Accessed 21 December 2020.
- ↑ Sanford Guide to Antimicrobial Therapy 2010